A detailed history of Point72 Hong Kong LTD transactions in Natera, Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 3,401 shares of NTRA stock, worth $362,308. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,401
Previous 36,571 90.7%
Holding current value
$362,308
Previous $2.29 Million 86.42%
% of portfolio
0.02%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$59.21 - $92.9 $1.96 Million - $3.08 Million
-33,170 Reduced 90.7%
3,401 $311,000
Q4 2023

Feb 14, 2024

BUY
$37.55 - $62.64 $1.37 Million - $2.29 Million
36,571 New
36,571 $2.29 Million
Q2 2022

Aug 15, 2022

SELL
$28.13 - $44.54 $63,826 - $101,061
-2,269 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$30.32 - $91.33 $68,796 - $207,227
2,269 New
2,269 $92,000
Q3 2021

Nov 15, 2021

SELL
$100.17 - $126.36 $354,201 - $446,808
-3,536 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$86.05 - $119.72 $304,272 - $423,329
3,536 New
3,536 $401,000
Q1 2021

May 17, 2021

SELL
$91.47 - $124.36 $16,098 - $21,887
-176 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$66.66 - $111.74 $11,732 - $19,666
176 New
176 $18,000
Q2 2020

Aug 14, 2020

SELL
$26.36 - $49.86 $9,647 - $18,248
-366 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$17.27 - $40.17 $6,320 - $14,702
366 New
366 $11,000
Q2 2019

Aug 14, 2019

SELL
$17.75 - $27.58 $14,963 - $23,249
-843 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$11.34 - $20.62 $6,940 - $12,619
612 Added 264.94%
843 $17,000
Q4 2018

Feb 14, 2019

SELL
$12.32 - $24.38 $58,335 - $115,439
-4,735 Reduced 95.35%
231 $3,000
Q3 2018

Nov 14, 2018

BUY
$18.82 - $28.96 $93,460 - $143,815
4,966 New
4,966 $119,000

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $10.3B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.